Immunic to Attend Investor and Scientific Conferences in May 2024

Immunic, Inc., a biotechnology firm focused on developing orally administered small molecule therapies to treat chronic inflammatory and autoimmune diseases, has outlined its participation in several key investor and scientific conferences this May.

From May 12th to 14th and 21st to 22nd, Jessica Breu, Vice President of Investor Relations and Communications at Immunic, will attend Bio€quity Europe 2024 in San Sebastián, Spain, both in person and virtually. During this event, Breu will engage in one-on-one meetings with investors.

During the Digestive Disease Week (DDW) 2024, held from May 18th to 21st in Washington, DC, Franziska Buriánek, M.D., Senior Medical Director at Immunic, will present results from the company's phase 1b trial of IMU-856. This investigational drug, an orally available molecule that targets SIRT6, aims to treat celiac disease by modulating systemic activity. Buriánek’s presentation, titled "First In Human Trial Of IMU-856, An Orally Available Epigenetic Modulator Of Barrier Regeneration For The Treatment Of Celiac Disease," will be part of the "Since Sliced Bread: Best in Celiac 2024" session on May 20th from 2:00 to 3:30 pm EDT. Attendees can access the presentation on Immunic's website.

Furthermore, during the Consortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting taking place from May 29th to June 1st in Nashville, TN, Robert J. Fox, M.D., from the Mellen Center for Multiple Sclerosis at the Cleveland Clinic, will present interim data from Immunic’s phase 2 CALLIPER trial of vidofludimus calcium (IMU-838). This trial focuses on the drug’s impact on serum neurofilament in progressive multiple sclerosis patients. His poster presentation is scheduled for May 30th from 5:15 to 7:15 pm CDT and will also be available on Immunic's website.

Additionally, at the XXIII National Congress of Neurology held from May 30th to June 2nd in Golden Sands, Bulgaria, Sonya Ivanova Hristova-Chakmakova, M.D., Assistant Professor at the Multipro for Active Treatment in Neurology and Psychiatry «St. Naum», Sofia, Bulgaria, will present data from the same CALLIPER trial. Her presentation titled "Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial" will take place on May 30th at 2:00 pm EEST. This will also be accessible via Immunic’s website.

Immunic, Inc., listed on the Nasdaq as IMUX, is dedicated to advancing therapies for significant health challenges. Its leading program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 trials for relapsing and progressive multiple sclerosis, respectively, and has demonstrated therapeutic benefits in earlier phase 2 trials for relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. The drug combines neuroprotective, anti-inflammatory, and antiviral properties. Another compound, IMU-856, targets SIRT6 to restore intestinal barrier function, currently preparing for a phase 2 trial for celiac disease. IMU-381, still in preclinical stages, aims to address gastrointestinal diseases specifically.